Connect Biopharma Reports Revenue Decline and Increased Net Losses for Q3 2025

Connect Biopharma Holdings Limited reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a significant decline in revenue and an increase in net losses compared to the previous fiscal period. The company generated $16,000 in license and collaboration revenue for the third quarter, a stark decrease from $1.2 million in the same quarter of 2024. For the nine-month period, revenue fell to $64,000 from $25.3 million, primarily due to the absence of milestone payments and reduced activity under its collaboration agreement with Simcere Pharmaceutical Co., Ltd.

Operating expenses for Connect Biopharma increased to $17.7 million in the third quarter, up from $15.1 million in the prior year, driven by higher research and development costs associated with the ongoing development of its lead product candidate, rademikibart. Research and development expenses rose to $11.1 million from $9.0 million year-over-year, reflecting the initiation of two Phase 2 clinical trials. General and administrative expenses also saw a slight increase, totaling $6.6 million compared to $6.1 million in the previous year, attributed to higher professional fees as the company transitions to a more U.S.-centric operational model.

The net loss for the third quarter was $17.2 million, or $0.31 per share, compared to a net loss of $12.9 million, or $0.23 per share, in the same quarter of 2024. For the nine-month period, the net loss escalated to $40.4 million, or $0.73 per share, from $6.7 million, or $0.12 per share, in the prior year. The increase in net loss was primarily due to the significant drop in revenue and higher operating expenses. The company reported cash, cash equivalents, and short-term investments of $54.8 million as of September 30, 2025, which management believes will be sufficient to meet its cash requirements for at least the next year.

In terms of strategic developments, Connect Biopharma has made notable progress in its collaboration with Simcere, which includes an exclusive license agreement for the development and commercialization of rademikibart in Greater China. The agreement includes potential milestone payments totaling up to $123 million, although one milestone payment lapsed in 2025 due to unmet deadlines. The company also presented data at the European Respiratory Society Congress 2025, highlighting improvements in lung function and asthma control among patients in its clinical trials.

Looking ahead, Connect Biopharma anticipates reporting topline data from its ongoing Phase 2 acute exacerbation studies in asthma and COPD in the first half of 2026. The company remains focused on advancing its clinical programs while managing its financial resources amid a challenging economic environment. The potential for future revenue generation will depend on the successful development and commercialization of rademikibart and the achievement of remaining milestones under its collaboration agreements.